BR112013011152A2 - proteína beta-glucocerebrosidase recombinante variante, composição e uso da proteína betaglucocerebrosidase recombinante variante - Google Patents

proteína beta-glucocerebrosidase recombinante variante, composição e uso da proteína betaglucocerebrosidase recombinante variante

Info

Publication number
BR112013011152A2
BR112013011152A2 BR112013011152A BR112013011152A BR112013011152A2 BR 112013011152 A2 BR112013011152 A2 BR 112013011152A2 BR 112013011152 A BR112013011152 A BR 112013011152A BR 112013011152 A BR112013011152 A BR 112013011152A BR 112013011152 A2 BR112013011152 A2 BR 112013011152A2
Authority
BR
Brazil
Prior art keywords
protein variant
recombinant beta
glucocerebrosidase protein
composition
glucocerebrosidase
Prior art date
Application number
BR112013011152A
Other languages
English (en)
Portuguese (pt)
Inventor
Hung Do
Original Assignee
Callidus Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Callidus Biopharma Inc filed Critical Callidus Biopharma Inc
Publication of BR112013011152A2 publication Critical patent/BR112013011152A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112013011152A 2010-11-08 2011-11-08 proteína beta-glucocerebrosidase recombinante variante, composição e uso da proteína betaglucocerebrosidase recombinante variante BR112013011152A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41133110P 2010-11-08 2010-11-08
US41218010P 2010-11-10 2010-11-10
PCT/US2011/059731 WO2012064709A2 (en) 2010-11-08 2011-11-08 Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity

Publications (1)

Publication Number Publication Date
BR112013011152A2 true BR112013011152A2 (pt) 2016-11-29

Family

ID=46051505

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013011152A BR112013011152A2 (pt) 2010-11-08 2011-11-08 proteína beta-glucocerebrosidase recombinante variante, composição e uso da proteína betaglucocerebrosidase recombinante variante

Country Status (19)

Country Link
US (4) US8962564B2 (cg-RX-API-DMAC7.html)
EP (2) EP2638152B1 (cg-RX-API-DMAC7.html)
JP (2) JP6073796B2 (cg-RX-API-DMAC7.html)
KR (1) KR101901467B1 (cg-RX-API-DMAC7.html)
CN (2) CN105296447A (cg-RX-API-DMAC7.html)
BR (1) BR112013011152A2 (cg-RX-API-DMAC7.html)
CA (1) CA2817011C (cg-RX-API-DMAC7.html)
CY (1) CY1118843T1 (cg-RX-API-DMAC7.html)
DK (1) DK2638152T3 (cg-RX-API-DMAC7.html)
ES (2) ES2743825T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20161560T1 (cg-RX-API-DMAC7.html)
HU (1) HUE030932T2 (cg-RX-API-DMAC7.html)
LT (1) LT2638152T (cg-RX-API-DMAC7.html)
PL (1) PL2638152T3 (cg-RX-API-DMAC7.html)
PT (1) PT2638152T (cg-RX-API-DMAC7.html)
RS (1) RS55405B1 (cg-RX-API-DMAC7.html)
SI (1) SI2638152T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600431B (cg-RX-API-DMAC7.html)
WO (1) WO2012064709A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020157248A1 (en) * 2019-02-01 2020-08-06 Oxyrane Uk Ltd Glucocerebrosidase polypeptides
CN113795575A (zh) 2019-02-04 2021-12-14 自由行疗法有限公司 多核苷酸
US20220325265A1 (en) 2019-09-09 2022-10-13 Hoffmann-La Roche Inc. Glucocerebrosidase mutants
WO2021199039A1 (en) * 2020-03-29 2021-10-07 Yeda Research And Development Co. Ltd. Variants of beta-glucocerebrosidase for use in treating gaucher disease
KR20230042513A (ko) * 2020-07-29 2023-03-28 프리라인 테라퓨틱스 리미티드 폴리펩티드
WO2023145814A1 (ja) * 2022-01-31 2023-08-03 株式会社日本触媒 向上した酵素活性または向上した安定性を有する組換えグルコセレブロシダーゼタンパク質
JPWO2023145813A1 (cg-RX-API-DMAC7.html) * 2022-01-31 2023-08-03
WO2023145812A1 (ja) * 2022-01-31 2023-08-03 株式会社日本触媒 グルコセレブロシダーゼ活性を有する糖鎖付加タンパク質
WO2023198661A1 (en) 2022-04-12 2023-10-19 F. Hoffmann-La Roche Ag Fusion proteins targeted to the central nervous system
CN121406674A (zh) * 2022-10-08 2026-01-27 凌意(杭州)生物科技有限公司 用于治疗GCase缺乏相关疾病的多核苷酸
AU2024394235A1 (en) * 2023-12-08 2026-06-11 Denali Therapeutics Inc. Modified glucocerebrosidase polypeptides and methods of use thereof
TW202617982A (zh) * 2024-06-24 2026-05-01 美商戴納立製藥公司 包含經修飾之葡萄糖腦苷脂酶多肽之融合蛋白及其方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03503721A (ja) * 1988-12-23 1991-08-22 ジェンザイム コーポレイション 酵素的に活性な組換えグルコセレブロシダーゼ
JP2893481B2 (ja) 1988-12-23 1999-05-24 ジェンザイム コーポレイション 酵素的に活性な組換えグルコセレブロシダーゼ
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
NZ500694A (en) 1997-04-30 2001-09-28 Univ Minnesota Use of chimeric mutational vector (CMV), a macromolecule and a ligand for cell surface receptor adhesion molecule (clatherin) in gene therapy; the CMV vector derived from REC2 homologous pairing with Ustilago maydis
EP1027069B1 (en) * 1997-10-29 2006-07-26 Genzyme Corporation Gene therapy for gaucher disease
IL141403A0 (en) 1998-08-28 2002-03-10 Univ Duke Deleted adenoviruses and methods of making and administering the same
IL150314A0 (en) 1999-12-30 2002-12-01 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
US20020127219A1 (en) * 1999-12-30 2002-09-12 Okkels Jens Sigurd Lysosomal enzymes and lysosomal enzyme activators
IL152110A0 (en) 2000-04-06 2003-07-31 Exegenics Inc Expression system for efficiently producing clinically effective lysosomal enzymes (glucocerebrosidase)
AU2001267337A1 (en) * 2000-06-30 2002-01-14 Maxygen Aps Peptide extended glycosylated polypeptides
US7855063B2 (en) * 2003-04-16 2010-12-21 Yeda Research And Development Co. Ltd. Partially deglycosylated glucocerebrosidase polypeptide and crystals thereof
WO2005089047A2 (en) 2004-03-18 2005-09-29 Glycofi, Inc. Glycosylated glucocerebrosidase expression in fungal hosts
AU2008245578A1 (en) * 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
KR101789000B1 (ko) * 2007-05-22 2017-10-20 아미쿠스 세라퓨틱스, 인코포레이티드 이소파고민과 이의 유도체를 제조하는 새로운 방법
US9150849B2 (en) 2007-11-02 2015-10-06 The Scripps Research Institute Directed evolution using proteins comprising unnatural amino acids
EP2220218A4 (en) 2007-11-02 2010-12-08 Scripps Research Inst GENETICALLY ENCODED BORONATE AMINO ACID

Also Published As

Publication number Publication date
HRP20161560T1 (hr) 2016-12-30
CY1118843T1 (el) 2018-01-10
KR20140009238A (ko) 2014-01-22
US9566316B2 (en) 2017-02-14
US8962564B2 (en) 2015-02-24
WO2012064709A3 (en) 2012-08-02
US20150216950A1 (en) 2015-08-06
US20170157220A1 (en) 2017-06-08
EP2638152B1 (en) 2016-08-31
RS55405B1 (sr) 2017-04-28
US20160184408A1 (en) 2016-06-30
EP3144386A1 (en) 2017-03-22
US9254313B2 (en) 2016-02-09
JP2017099390A (ja) 2017-06-08
JP6073796B2 (ja) 2017-02-01
US9821038B2 (en) 2017-11-21
JP2014500722A (ja) 2014-01-16
CA2817011C (en) 2019-04-02
EP3144386B1 (en) 2019-05-29
CA2817011A1 (en) 2012-05-18
KR101901467B1 (ko) 2018-11-02
ES2604490T3 (es) 2017-03-07
PT2638152T (pt) 2016-10-25
CN103314105B (zh) 2015-11-25
WO2012064709A2 (en) 2012-05-18
JP6457559B2 (ja) 2019-01-23
US20130344054A1 (en) 2013-12-26
HUE030932T2 (en) 2017-06-28
EP2638152A2 (en) 2013-09-18
SI2638152T1 (sl) 2016-12-30
PL2638152T3 (pl) 2017-02-28
CN105296447A (zh) 2016-02-03
ES2743825T3 (es) 2020-02-20
DK2638152T3 (en) 2016-12-12
LT2638152T (lt) 2016-12-12
SMT201600431B (it) 2017-01-10
EP2638152A4 (en) 2014-04-09
CN103314105A (zh) 2013-09-18

Similar Documents

Publication Publication Date Title
IL280949B (en) Ph20 polypeptide variants, formulations and uses thereof
HRP20190137T1 (hr) Stabilne formulacije polipeptida i njihova uporaba
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
BR112013014231A2 (pt) composição de higiene pessoal e uso da composição de higiene pessoal
BRPI1008061A8 (pt) polipeptídeos recombinantes estendidos e composições compreendendo os mesmos
HUE055505T2 (hu) Anti-CGRP készítmények és alkalmazásuk
HUE045845T2 (hu) Módosított relaxin polipeptidek és felhasználásuk
BR112012013148A2 (pt) formulação farmacêutica e uso
IL232073A0 (en) Recombinant human naglu protein and its uses
HUE043040T2 (hu) Poliszacharid keresztkötéseket tartalmazó fehérje készítmény és/vagy formula
BRPI0921699A2 (pt) complexo antioxidante, composicoes cosmeticas e farmaceutica contendo o referido complexo e uso deste complexo
BR112014004936A2 (pt) polipeptídeo glicosilado e composição de drogas contendo referido polipeptídeo
BR112012003800A2 (pt) composição, peptídeo, e formulação farmacêutica.
BRPI1008887A2 (pt) peptídeos de foxm1 e vacinas contendo os mesmo
BR112013030395A2 (pt) polipeptídeo, polinucleotídeo, vetor, composição imunogênica, vacina, e, uso de uma composição imunogênica
HUE050438T2 (hu) Rekombináns fehérjék és terápiás alkalmazásuk
BRPI1006953A2 (pt) composição farmacêutica, e, uso de uma composição
BR112013003530A2 (pt) ''produto farmacêutico, kit, uso e preparações''
BR112013015819A2 (pt) construção de dna, composição farmacêutica e uso de uma construção de dna
IL229926A (en) Neil3 peptides and vaccines including the same
BRPI0915527A2 (pt) pepitídeos, composição farmacêutica e exossomos compreendendo os mesmos, métodos e usos
BR112012016736A2 (pt) composição , formulação farmacêutica e uso da composição"
EP2557088A4 (en) PHYSIOLOGICALLY ACTIVE PEPTIDES
PT2525827T (pt) Formulações farmacêuticas de loratadina para encapsulação e combinações das mesmas
BR112013023575A8 (pt) novo derivado de octaidrotienoquinolina, composição farmacêutica compreendendo derivado, e uso destes

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: AMICUS THERAPEUTICS, INC. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements